BIO 2004: Call for closer Singapore-Australia biotech ties
09 June, 2004 by Melissa TrudingerThe Singapore and Australian biotechnology industries have synergies that should be exploited, the director of the Singapore Economic Development Board, Dr Swan-Gin Beh, has told a session at the BIO 2004 conference in San Francisco this week.
Sirtex to manufacture isotopes in US
08 June, 2004 by Graeme O'NeillSydney biomedical company Sirtex Medical Ltd (ASX:SRX) has announced it has purchased a US manufacturing site in Wilmington, Massachusetts, at a cost of US$990,000, funded though a mortgage over the property.
BIO 2004: Vics restate biotech dominance aim
07 June, 2004 by Melissa TrudingerVictorian premier Steve Bracks has used the BIO 2004 conference, which kicked off in San Francisco on Sunday, as a platform to reiterate the state's ambitious plan to become one of the top five biotechnology locations globally by 2010.
Tropical science: Survival of the fittest
02 June, 2004 by Susan WilliamsonHer 30-year career has taken her from Sydney to Wales to South Africa, from biology at Wollongong to nuclear science at Australia's only research reactor. And now Prof Helen Garnett has a new challenge, as vice-chancellor of the Northern Territory's new Charles Darwin University.
Events down under
01 June, 2004 by Melissa TrudingerA full roster of conferences in Australia and its Asia-Pacific neighbours make the region a good place to visit this year. To start with, Australia's BIO equivalent, AusBiotech2004, will this year be held in Brisbane from November 7-10, with a theme of 'Going Global'.
Aussies you'll meet at BIO
01 June, 2004 by Melissa TrudingerAustralia is home to a thriving and dynamic biotechnology industry with a firm footing in the world-class research base found in the universities and research institutions 'Down Under'.
BIO profile: Brian Whan, Molecular Plant Breeding CRC
01 June, 2004 by Graeme O'NeillWhen the Victorian Department of Agriculture's Werribee research farm advertised for a 'Semi-Dwarf Wheat Breeder' in the early 1970s, Bryan Whan applied -- his qualifications measured up, even if his height exceeded specification.
Venture capital: adventurous times in biotech
01 June, 2004 by Renate KrellePositive forces are at work in Australian venture capital circles, writes Renate Krelle.
Trials without error: Australia's clinical capabilities
01 June, 2004 by Renate KrelleThe secret's out -- Australia is a great place to do clinical trials and contract research, as Renate Krelle discovers.
BIO profile: Harry Karelis, Biotech Capital
01 June, 2004 by Renate KrelleUK and European biotechs may not have heard of Australian historian Geoffrey Blainey. But Harry Karelis, of Sydney venture capitalist Biotech Capital, says both British and continental biotechs are just as conscious as Australians are of Blainey's most famous concept -- the tyranny of distance.
BIO profile: Andy Gearing, BioComm
01 June, 2004 by Melissa TrudingerDr Andy Gearing believes wholeheartedly that big pharma and big biotech overseas should take a closer look at what the Australian biotechnology and life sciences sector has to offer.
BIO profile: John Mattick, Institute for Molecular Bioscience
01 June, 2004 by Melissa TrudingerAustralia's research institutes and industry have a mutual responsibility, says Prof John Mattick -- to work together to translate academic ideas into ideas for development and commercialisation.
BIO profile: Mervyn Jacobson, Genetic Technologies
01 June, 2004 by Melissa TrudingerA keen fascination in the creative ideas of others and a willingness to take risks are hallmarks of Australian biotechnology entrepreneur Dr Mervyn Jacobson's outlook on life.
BIO profile: Jurgen Michaelis, Bio Innovation SA
01 June, 2004 by Graeme O'NeillStart-ups are the easy bit -- it's the quality and consistency of post-natal care that determines whether young biotechnology companies will survive, according to Dr Jurgen Michaelis, the man behind the rapid rise of South Australia's biotechnology industry.
BIO profile: Alison Coutts, eG Capital
01 June, 2004 by Iain ScottOne of the most serendipitous moments in the recent history of Australian biobusiness occurred when Alison Coutts met Mark Fordree, Iain Scott learns.
